Clinical Trials on CNS in Netherlands

Total 126 results

Sanofi

Completed

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

France, United States, Canada, Czechia, Estonia, Netherlands, Russian Federation, Slovakia, Spain, Ukraine
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)

Multiple Sclerosis

Spain, France, Czechia, Slovakia, Italy, Hungary, Austria, Denmark, Netherlands, Poland
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
Biogen

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (ENHANCE)

Multiple Sclerosis

United States, Finland, Italy, United Kingdom, Bulgaria, Serbia, Russian Federation, Lithuania, Poland, Czech Republic, Netherlands
Genzyme, a Sanofi Company

Active, not recruiting

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (TERIKIDS)

Multiple Sclerosis

Belgium, United States, Bulgaria, Canada, China, Estonia, France, Greece, Israel, Lebanon, Lithuania, Morocco, Netherlands, Portugal, Russian Federation, Serbia, Spain, Tunisia, Turkey, Ukraine, United Kingdom
EMD Serono

Terminated

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) (ATAMS)

Relapsing Multiple Sclerosis

United States, Sweden, Australia, Czech Republic, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Ukraine, Netherlands, Canada, France, Austria, Lebanon, Switzerland, Belgium
Bayer

Completed

Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis

Multiple Sclerosis

Belgium, Italy, Spain, France, Switzerland, Israel, Czech Republic, Canada, Austria, Poland, Germany, Netherlands, United Kingdom, Hungary, Portugal, Finland, Norway, Sweden, Slovenia, Denmark
UCB Pharma
Biogen

Terminated

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Multiple Sclerosis

United States, France, Germany, Spain, Canada, Netherlands, Belgium, Hungary, Sweden, United Kingdom, Finland
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United Kingdom, United States, Canada, Belgium, Czech Republic, France, Germany, Netherlands
Biogen

Completed

Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (PERSIST)

Multiple Sclerosis

Sweden, France, United Kingdom, Germany, Denmark, Netherlands, Slovakia, Switzerland, Norway, Portugal
Novartis Pharmaceuticals

Recruiting

The Gilenya Pregnancy Registry

Multiple Sclerosis

Denmark, Spain, Switzerland, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Cyprus, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Mexico, Netherlands, Norway, Poland, ... and more
Sanofi

Completed

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

United States, Austria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Sweden, Switzerland, Turkey, Ukraine, United Kingdom
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Novartis Pharmaceuticals

Recruiting

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Italy, Spain, United States, Germany, France, Serbia, Austria, Brazil, Bulgaria, Canada, Croatia, Estonia, Latvia, Mexico, Poland, Puerto Rico, Russian Federation, Sweden, Turkey, Ukraine, United Kingdom, Lithuania, Netherlands, Slovakia and more
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Hoffmann-La Roche

Active, not recruiting

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Multiple Sclerosis

Canada, United Kingdom, Belgium, Brazil, Croatia, Mexico, Slovakia, Ireland, Netherlands, Estonia, Norway, Denmark, Italy, Poland, Spain, Bulgaria, France, Turkey, Portugal, Sweden, Argentina, Kuwait, Slovenia, Czechia, Hungary, Finland
Biogen

Completed

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice (LIBERATE)

Multiple Sclerosis

France, Spain, Germany, Netherlands, Argentina, Czechia, Israel, Portugal, United Arab Emirates, Canada, Norway, Lebanon, Ireland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)

Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
GlaxoSmithKline

Completed

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States, Bulgaria, Russian Federation, Spain, Germany, Czechia, Netherlands, Norway, Italy, Canada, Denmark
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Immunic AG

Active, not recruiting

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Multiple Sclerosis

United States, Germany, Netherlands, Bulgaria, Serbia, Canada, Czechia, Moldova, Republic of, North Macedonia, Poland, Romania, Ukraine
Sanofi

Completed

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

Multiple Sclerosis

Belgium, United States, Australia, Austria, Belarus, Canada, Chile, China, Czech Republic, Estonia, France, Germany, Greece, Mexico, Netherlands, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Thailand, Tunisia, Turkey, Ukraine, United...
GlaxoSmithKline

Completed

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Multiple Sclerosis

Italy, Germany, Spain, United Kingdom, Australia, Netherlands, New Zealand, Russian Federation, France, Canada, Austria, Poland, Finland, Norway
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel
Merck KGaA, Darmstadt, Germany

Completed

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)

Multiple Sclerosis

Hungary, Belgium, Portugal, Slovakia, France, Finland, Poland, Denmark, Czechia, Spain, United Kingdom, Italy, Austria, Greece, Lithuania, Netherlands, Norway, Sweden
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
Biogen

Terminated

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (AFFINITY)

Multiple Sclerosis

United States, Italy, Spain, Belgium, Germany, Switzerland, Australia, Hungary, France, Poland, United Kingdom, Czechia, Israel, Canada, Netherlands
Hoffmann-La Roche

Active, not recruiting

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

Multiple Sclerosis

United States, Spain, Austria, Czechia, Italy, Hungary, Australia, Portugal, Serbia, Canada, Germany, United Kingdom, Poland, Romania, Croatia, Israel, Belgium, Bulgaria, Estonia, Switzerland, Mexico, Lithuania, New Zealand, France, Slo... and more
Novartis

Completed

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Relapsing Multiple Sclerosis

Germany, Italy, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Multiple Sclerosis, Relapsing-Remitting

Belgium, United Kingdom, Australia, Netherlands, Ireland, Norway, Turkey, Estonia, Denmark, Germany, Italy, Spain, Switzerland, France, Finland, Sweden, Czechia
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Novartis

Completed

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Greece, Russian Federation, Switzerland, Germany, Israel, Ireland, Belgium, Finland, United Kingdom, Netherlands, Canada, Romania, Hungary, Poland, Czech Republic, Australia, Estonia, France, Slovakia, South Africa, Sweden, Turkey
Sanofi

Terminated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (TERACLES)

Multiple Sclerosis Relapse

Spain, Germany, Sweden, Canada, Austria, Korea, Republic of, Russian Federation, Greece, Hungary, Italy, Belgium, Slovakia, Tunisia, France, Australia, United States, Argentina, Brazil, Chile, Colombia, Denmark, Estonia, Finland, Lith... and more
Biogen

Completed

Dimethyl Fumarate (DMF) Observational Study (ESTEEM)

Multiple Sclerosis

United States, Denmark, Italy, Netherlands, Switzerland, Canada, Australia, New Zealand, United Kingdom, Slovakia, Austria, Hungary, Czechia, Portugal, Germany, Spain, Poland, Puerto Rico, France, Argentina, Ireland, Norway
Actelion

Completed

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Poland, Ukraine, United Kingdom, United States, Germany, Spain, Bulgaria, Romania, Serbia, Canada, Finland, Sweden, Russian Federation, Hungary, Czechia, Netherlands, Israel, Switzerland, Austria, France
EMD Serono
Pfizer

Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

United States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (GEMINI 2)

Relapsing Multiple Sclerosis

United States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Korea, Republic of, Latvia, Netherlands, Norway, Portugal, Puerto Rico, Russian Federation, Serbia, Slovakia, Spai... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I)

Relapsing Multiple Sclerosis

Belgium, Italy, United States, Croatia, Spain, Netherlands, Switzerland, Thailand, Israel, Czechia, Estonia, Poland, France, Bulgaria, Russian Federation, Germany, Turkey, Slovakia, Australia, Denmark, Greece, Argentina, India, Hungary, United Kingdom and more
Genzyme, a Sanofi Company
Bayer

Completed

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Multiple Sclerosis, Relapsing-Remitting

Netherlands, Spain, Germany, Israel, United Kingdom, Canada, Australia, United States, Italy, Argentina, Croatia, Russian Federation, Poland, Czechia, Belgium, France, Brazil, Austria, Denmark, Mexico, Serbia, Sweden, Ukraine
Biogen

Completed

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (ADVANCE)

Relapsing Multiple Sclerosis

United States, Germany, Russian Federation, India, New Zealand, Spain, Belgium, Colombia, Canada, Bulgaria, Serbia, Greece, Peru, Ukraine, Poland, United Kingdom, Croatia, France, Romania, Chile, Czech Republic, Mexico, Estonia, Georgia, Latv... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Bayer

Completed

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (Beyond)

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, United States, Canada, France, Switzerland, Ireland, Italy, Australia, Spain, Austria, Germany, Brazil, Netherlands, Poland, Russian Federation, Hungary, Slovenia, Argentina, Ukraine, Greece, Sweden, Finland, Latvia, No... and more
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
Genzyme, a Sanofi Company

Completed

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (TOPAZ)

Relapsing Remitting Multiple Sclerosis

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Germany, Israel, Italy, Mexico, Netherlands, Poland, Russian Federation, Spain, Sweden, Ukraine, United Kingdom
Bayer

Completed

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, Sweden, United States, France, Switzerland, Ireland, Canada, Australia, Brazil, Austria, Poland, Germany, Hungary, Netherlands, Russian Federation, Spain, Argentina, Slovenia, Greece, Finland, Denmark, Ukraine, Italy, L... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance)

Relapsing Multiple Sclerosis

United States, Mexico, Hungary, China, Germany, Italy, Peru, Poland, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Tunisia, Netherlands, Argentina, Georgia, Hong Kong, Kenya, Dominican Republic, Finland, North Macedonia, Serb...
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Relapsing Multiple Sclerosis

China, Spain, Switzerland, Taiwan, United States, Italy, Austria, Belgium, Saudi Arabia, United Arab Emirates, Latvia, Poland, Argentina, India, Croatia, Bulgaria, Malaysia, Slovakia, Israel, Lebanon, Guatemala, Netherlands, Colombia, Chil... and more

Clinical Trials on CNS in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations